Aeovian Pharmaceuticals is a research stage biopharmaceutical company aiming to discover, develop and commercialize innovative treatments for rare and age-related diseases. It is designing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress.

Lead compounds are highly selective, potential mTORC1 inhibitors. Proprietary platform is supported by an extensive intellectual property portfolio from the Buck Institute of Novato, California.